Depudecin makes a debut
نویسندگان
چکیده
منابع مشابه
Open Payments Program (aka the Sunshine Act) makes public debut.
W ith government funding for bio-medical research stagnant or declining, scientists rely more than ever on industry support. Yet although that support is indispensible, it poses delicate challenges: Scientists and doctors are sometimes tempted to decide what's best for a sponsoring company rather than for patients. These conflicts of interest have sparked growing calls for transparency into ind...
متن کاملA German Education and a Brilliant Debut
The name of Theodor Schwann (1810-1882) is familiar to anybody involved in the neurological sciences. When prompted with the name of this German biologist, the first thing that comes to mind is the Schwann cell. To have his name associated with a particular type of cell seems most appropriate since Schwann was one of the founders of the cell doctrine. This theory revolutionized biology by estab...
متن کاملThe debut of PMC Biophysics
Firstly, the open access movement is gathering strength. Pioneered by PMC Biophysics's parent company, BioMed Central, open access allows any reader immediate free access to published articles, encouraging the widest possible spread of knowledge. Archiving in multiple repositories ensures the long-term preservation of scientific research, and electronic publication enables the inclusion of mult...
متن کاملSarcoidosis. Debut as orbital pseudotumour.
CASE REPORT 78 year-old female patient being investigated for a left orbital pseudotumour of 17 days onset. She had proptosis, pain, with no limitation of eye movements, periorbital oedema, and upper eyelid ptosis, compatible with an orbital pseudotumour. The MRI showed an upper outer left orbital mass adjacent to the side of eyeball and an increase in soft tissue at the level of lacrimal gland...
متن کاملInfantile-onset Pompe disease with neonatal debut
Rationale: Infantile-onset Pompe disease, also known as glycogen storage disease type II, is a progressive and fatal disorder without treatment. Enzyme replacement therapy with recombinant human acid alpha-glucosidase (GAA) enhances survival; however, the best outcomes have been achieved with early treatment. Patient concerns:We report a case of a newborn with infantile-onset Pompe disease diag...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the National Academy of Sciences
سال: 1998
ISSN: 0027-8424,1091-6490
DOI: 10.1073/pnas.95.7.3335